ZIP 016
Alternative Names: ZIP-016Latest Information Update: 24 Dec 2022
At a glance
- Originator Ziphius Vaccines
- Class RNA
- Mechanism of Action RNA replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cystic fibrosis
Most Recent Events
- 12 Dec 2022 ZIP 016 is available for licensing as of 12 Dec 2022. https://ziphius.org/pipeline
- 12 Dec 2022 Preclinical trials in Cystic fibrosis in Belgium (Parenteral) before December 2022 (Ziphius Vaccines pipeline, December 2022)